Received Mar 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | — | — |
Grave's disease; they noticed symptoms/have an allergy to ingredient in COVID-19 vaccine; This is a spontaneous report received from a Consumer or other non HCP from medical information team. A male patient received BNT162b2 omicron (kp.2) (COMIRNATY (2024-2025 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, single), for COVID-19 immunization, reaction(s): "allergy to ingredient in COVID-19 vaccine"; Bnt162b2 (DOSE 2, single), for COVID-19 immunization, reaction(s): "allergy to ingredient in COVID-19 vaccine". The following information was reported: GRAVES' DISEASE (medically significant), outcome "unknown", described as "Grave's disease"; ALLERGY TO VACCINE (non-serious), outcome "unknown", described as "they noticed symptoms/have an allergy to ingredient in COVID-19 vaccine". Clinical course: The patient received 3 doses. The patient had an allergy to ingredient in COVID-19 vaccine, clarified a PEG, 3350 or something, allergy, an allergy to Miralax. Said the ingredient in Miralax was also in the vaccine. The patient was after 3rd dose and had Grave's disease, confirmed spelling with caller, hyperthyroid. The patient was given medicine. No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.